Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

n of ($131,330). (5) To exclude additional interest expense as a result of adopting ASC 470-20 of $4,114 and to exclude amortization of the premium on debt acquired from Indevus of ($94). (6) To exclude changes in fair value of financial instruments, net. (7) To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates. Three Months Ended Dec. 31, 2008 Actual (unaudited) Reported (GAAP) Adjustments Adjusted -------- ----------- -------- Total Revenues $347,336 - $347,336 Costs and expenses: Cost of revenues 76,681 (8,877) (1) 67,804 Selling, general and administrative 130,288 - 130,288 Research and development 27,967 (6,910) (2) 21,057 Purchased in-process research & development (530 ) 530 (3) - Operating income 112,930 15,257 128,187 Interest (income) expense, net 2,185 (3,752) (4) (1,567) Other (income) expense, net 2,588 (3,320) (5) (732) Income before income taxes 108,157 22,329 130,486 Income taxes 35,471 8,912 (6) 44,383 Net income $72,686 $13,417 $86,103 Diluted earnings per share $0.62 $0.74 Diluted weighted average shares 116,894 116,894 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of ope
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- UBM Medica US today announced the launch of ... information resource for neurologists and other healthcare providers to ... neurological disorders . The prevalence of ... access to dedicated information for healthcare providers who treat ... , 1 in 6 people are affected ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... 20, 2012   Sysmex America, Inc., a global leader ... today announced its 200th placement of Sysmex WAM ... Laboratory.  Sysmex WAM is now connecting nearly 600 sites ... U.S. and Canada. Sysmex WAM plays a key role ...
... Assured Pharmacy (Pinksheets: APHY), a leading specialty pharmacy group ... present at Anda,s 2012 Supply Chain Symposium on Thursday, ... in Palm Beach Gardens, Florida.  Assured Pharmacy has been ... dispensing controlled substances at pharmacies.   Anda ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 3
(Date:7/23/2014)... July 24, 2014 The routine ... UPMC greatly increases the likelihood of performing the ... and cancer, report researchers from the University of ... , The test, available at the UPMC/UPCI Multidisciplinary ... the chances of patients getting the correct initial ...
(Date:7/23/2014)... 23, 2014 Men and women who ... for life insurance based on national averages. The Quotes ... rates search to its comprehensive tool this year to ... . , Providers that are now underwriting plans ... reviewed in one or two clicks. The intelligent platform ...
(Date:7/23/2014)... Sellafield or Dounreay since the 1990s are not at ... published in the British Journal of Cancer ... Group at the University of Oxford and from Newcastle ... those who were under 25 and living near Sellafield ... cancer incidence from 1991-2006 between those living near these ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... PA) Asking patients if a suspicious skin lesion ... the spot is likely to be cancerous, according to ... of the Department of Dermatology at Temple University School ... JAMA Dermatology on July 23, 2014, found that ... accompanied by itching, while 28.2 percent involve pain. Non-melanoma ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
The Liz Claiborne eyewear collection features feminine, classic, progressive friendly designs that meet the needs of today's women. The high quality frames are modern, but not trendy....
Medicine Products: